Answers are grounded in this paper and cite their sources.
In the present study, we have designed some novel bisarylpiperazine derivatives as Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. Docking studies of the designed analogues were performed by molecular modeling software AutoDock 4.2 using HIV-1 Reverse Transcriptase (PDB ID: 1RT2) as receptor. Lipinskis Rule of Five (Ro5) parameters and toxicity parameters were predicted through online servers like Molinspiration and Osiris property explorer. Docking parameters such as binding free energy and predicted inhibitory constant (Ki) values of the designed analogues were compared with standard drugs Efavirenz and co-crystallized ligand TNK-651. Among the designed analogues, 1, 4, 8, 9, 12, 15, 27, 30, 37, 38, 39 and 43 showed significant and comparable binding free energy and predicted inhibitory constant values as that of standard drugs. These results indicate that, the designed analogues adopt a similar orientation and share the same binding mode as that of some of the classical Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) within the active site of Non-Nucleoside Inhibitory Binding Pocket (NNIBP) of HIV-1 reverse transcriptase.
No takes yet. Share an insight, caveat, or question.
Yadav et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: